Gedatolisib is currently being evaluated in combination with fulvestrant, with and without palbociclib, in patients with HR+/HER2− advanced breast cancer in a global Phase 3 clinical trial (VIKTORIA-1, NCT05501886). This evidence concerns the gene HR and breast cancer.